Renal Anemia - Pipeline Review, Q4 2010

Date: December 1, 2010
Pages: 31
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: R12257EB092EN
Leaflet:

Download PDF Leaflet

Renal Anemia - Pipeline Review, Q4 2010
Renal Anemia - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Renal anemia Pipeline Review, Q4 2010”, provides an overview of the Renal anemia therapeutic pipeline. This report provides information on the therapeutic development for Renal anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal anemia. “Renal anemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Renal anemia.
  • A review of the Renal anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Renal anemia pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • A snapshot of the global therapeutic scenario for Renal anemia.
  • A review of the Renal anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Renal anemia pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Introduction
Global Markets Direct Report Coverage
Renal Anemia Overview
Therapeutics Development
An Overview of Pipeline Products for Renal Anemia
Renal Anemia Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Renal Anemia Therapeutics Development
Lentigen Corporation
FibroGen, Inc.
Acceleron Pharma, Inc.
AplaGen GmbH
Renal Anemia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Discontinued Products
Renal Anemia - Featured News
Nov 29, 2010: Affymax And Takeda Confirm US Registration Strategy For Hematide Following Meeting with FDA
Nov 19, 2010: FibroGen To Present Phase IIa Results Of FG-4592 At American Society Of Nephrology Renal Week
Oct 26, 2010: Rockwell Medical Receives Soluble Ferric Pyrophosphate Patent For GMP Formulation In US
Oct 21, 2010: AMAG Reports Data Presentations At American Society Of Nephrology Renal Week Meeting
Sep 20, 2010: FibroGen Receives Chinese Clinical Trial Application Approval For FG-4592 In Treatment Of Anemia Associated With Chronic Kidney Disease
Aug 05, 2010: Affymax And Takeda Announce Preliminary US Registration Strategy For Hematide To Treat Anemia In Chronic Renal Failure
Jul 22, 2010: Akebia Initiates Phase IIa Clinical Study Of AKB-6548 For Treatment Of Anemia
Nov 17, 2009: FAIR-HF Study Results Show Significant Improvement In Chronic Heart Failure Patients’ Lives And Give A new Therapeutic Option To Healthcare Professionals
Jan 30, 2009: Patient Recruitment Resumes In FibroGen Phase II Study Of Investigational Oral HIF-PH Inhibitor, FG-4592/ASP1517, For The Treatment Of Anemia Associated With Chronic Kidney Disease
Jan 15, 2009: Lipoxen Reports Encouraging Phase I Interim Results Of ErepoXen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Renal Anemia, 2010
Products under Development for Renal Anemia – Comparative Analysis, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Pre-Clinical Stage Development, 2010
Lentigen Corporation, 2010
FibroGen, Inc., 2010
Acceleron Pharma, Inc., 2010
AplaGen GmbH, 2010
Assessment by Monotherapy Products, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 22

LIST OF FIGURES

Number of Products under Development for Renal Anemia, 2010
Products under Development for Renal Anemia – Comparative Analysis, 2010
Products under Development by Companies, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 20
Renal Anemia - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 33 pages
Renal Anemia - Pipeline Review, H2 2013 US$ 2,000.00 Sep, 2013 · 112 pages
Anemia - Pipeline Review, H2 2013 US$ 2,000.00 Aug, 2013 · 329 pages

Ask Your Question

Renal Anemia - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: